Linfoma No Hodgkin

More documents

Recommendations

Info

Cátedra de Hematología. Prof. Dra. Martha Nese | 2008alpha and zidovudine therapy in adult T-cell leukaemialymphoma: response and outcome in 15 patients.Br J Haematol 2001; 113: 779-78425. Hermine O, Allard I, Lévy V, et al.: A prospectivephase II clinical trial with the use of zidovudine andinterferon-alpha in the acute and lymphoma formsof adult T-cell leukemia/lymphoma. Hematol J 2002;3: 276-28226. A predictive model for aggressive non-Hodgkin’slymphoma. The International Non-Hodgkin’s LymphomaPrognostic Factors Project. N Engl JMed1993; 329: 987-99427. Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognosticsignificance of T-cell phenotype in aggressivenon-Hodgkin’s lymphomas. Groupe d’Etudesdes Lymphomes de l’Adulte (GELA). Blood1998; 92:76-8228. Sonnen R, Schmidt WP, Müller-Hermelink HK, et al.:The International Prognostic Index determines theoutcome of patients with nodal mature T-cell lymphomas.Br J Haematol 2005; 129: 366-37229. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognosticmodel from a retrospective multicentric clinicalstudy. Blood. 2004;103:2474–247930. Bekkenk MW, Vermeer MH, Jansen PM, et al. PeripheralT-cell lymphomas unspecified presenting inthe skin: analysis of prognostic factors in a group of82 patients. Blood. 2003;102:2213–221931. Go RS, Wester SM: Immunophenotypic and molecularfeatures, clinical outcomes, treatments, andprognostic factors associated with subcutaneouspanniculitis-like T-cell lymphoma: a systematicanalysis of 156 patients reported in the literature.Cancer 2004; 101: 1404-1332. Went P, Agostinelli C, Gallamini A, et al. Marker expressionin peripheral T-cell lymphoma: A proposedclinical-pathologic prognostic score. J Clin Oncol.2006;24:1–833. Niitsu N, Okabe-Kado J, Okamoto M, et al. Serumnm23-H1 protein as a prognostic factor in aggressivenon-Hodgkin lymphoma. Blood. 2001;97:1202–121034. Pescarmona E, Pignoloni P, Puopolo P, et al. p53over-expression identifies a subset of nodal peripheralT-cell lymphomas with a distinctive biologicalprofile and poor clinical outcome. J Pathol.2001;195: 361–366.35. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokinereceptor 3 and CC chemokine receptor 4expression in T-cell and NK-cell lymphomas withspecial reference to clinicopathological significancefor peripheral T-cell lymphoma, unspecified. ClinCancer Res. 2004;10:5494–550036. Rodriguez J, Munsell M, Yazji S, et al.: Impact ofhigh-dose chemotherapy on peripheral T-cell lymphomas.J Clin Oncol 2001;19: 3766-377037. Evens AM, Gartenshaus RB. Treatment of T-cellNon-Hodgkin’s Lymphoma. Curr Treat Opt Oncol.2004;5:289–30338. Escalon MP, Liu NS, Yang Y, et al. Prognostic factorsand treatment of patients with T-cell non-Hodgkinlymphoma. Cancer. 2005;103:2091–209839. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional(ACVBP regimen) compared with standardCHOP for poor-prognosis aggressive non-Hodgkinlymphoma. Blood. 2003;102:4284–428940. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy.Oncogene. 2005;24:6047–605741. Sallah S, Wan JY, Nguyen NP. Treatment of refractoryT-cell malignancies using gemcitabine. Br JHaematol. 2001;113:185–18742. Marchi E, Alinari L, Tani M, et al. Gemcitabine asfrontline treatment for cutaneous T-cell lymphoma.Cancer. 2005;104:2437–244143. Kurzrock R, Ravandi F. Purine analogues in advancedT-cell lymphoid malignancies. Elsevier. SeminHematol. 2006;43:S27–S34.44. Enblad G, Hagberg H, Erlanson M, et al. A pilot studyof alemtuzumab (anti-CD52 monoclonal antibody)therapy for patients with relapsed or chemotherapy-refractoryperipheral T-cell lymphomas. Blood.2004;103: 2920–2924.45. Weidmann E, Hess G, Krause SW, et al. Combinationchemo-immunotherapy using alemtuzumab,fludarabine, cyclophosphamide and doxorubin isan effective first-line regimen in peripheral T-celllymphoma [abstract]. Blood. 2004;104:2640 ª46. Dearden CE, Matutes E, Cazin B, et al. High remissionrate in T-cell prolymphocytic leukemia withCAMPATH-1H. Blood. 2001;98:1721–172647. Talpur R, Apisarnthanarax N, Ward S, et al. Treatmentof refractory peripheral T-cell lymphoma with DenileukinDifitox (ONTAK®). Leuk Lymph. 2002;43:121–12648. Mounier N, Gisselbrecht C, Briere J, et al. All aggressivelymphoma subtypes do not share similar outcomeafter front-line autotransplantation: a matchedcontrolanalysis by the Group d’Etude des Lymphomesde l’ Adulte (GELA). Ann Oncol. 2004;15:1790–179749. Jagasia MH, Morgan D, Goodman S, et al. Histologyimpacts the outcome of peripheral T-cell lymphomasafter high-dose chemotherapy and stem celltransplant. Leuk Lymph. 2004:45:2261–226750. Majhail NS, Burns LJ. Hematopoietic stem celltransplantation in the treatment of peripheral T-celllymphomas. Curr Hematol Rep. 2005;4:252–25951. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneichematopoietic stem cell transplantation providessustained long-term survival for patients withadult T-cell leukemia/ lymphoma. Leukemia.2005;19:829–83452. Chanan-Khan A, Islam T, Alam A, et al.: Long-termsurvival with allogeneic stem cell transplant and donorlymphocyte infusion following salvage therapywith anti-CD52 monoclonal antibody (Campath) ina patient with alpha/beta hepatosplenic T-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 45: 1673-5,200453. Corradini P, Dodero A, Zallio F, et al. Graft-versuslymphomaeffect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioningfollowed by allogeneic transplantation ofhematopoietic cells. J Clin Oncol. 2004;22:2172–2176.Bibliografía ALCL1. Mujahid A. Rizvi, Andrew M. Evens, Martin S. Tallman,Beverly P. Nelson, and Steven T. Rosen. T- cellnon- Hodgkin Lymphoma. Blood 2006;107: 1255 -12642. Harald Stein, Hans- Dieter Foss, Horst Dürkop, TheresaMrafioti, Georges Delsol, Karen Pulford, StefanoPileri, and Brunangelo Falini. CD30 + anaplasticlarge cell lymphoma: a review of its histopathologic,genetic and clinical features. Blood 2000;96:3681 -36953. Tilly H, Gaulard P, Lepage E, Dumontet C, DieboldJ, Plantier I, Berger F, Symann M, Petrella T, Leder58 ® Cátedra de Hematología. Abril 2008. Montevideo, Uruguay
Consenso Nacional de Linfoma no Hodgkinlin P, and Briere J for the Groupe d’Etudes des Lymphomesde l’Adulte. Primary Anaplastic Large -CellLymphoma in Adults: Clinical Presentation, Inmunophenotpe,and Outcome. Blood 1997;90:3727-37344. Carbone A, Gloghini A, Gaidano G, Dalla-FaveraR, and Falini B. BCL-6 Protein Expression in HumanPeripheral T-Cell Neoplasms is Restricted toCD30(+) Anaplastic Large-Cell Lymphomas. Blood1997; 90:2445-24505. Janik JE, Morris JC, Pittaluga S, MacDonald K, RaffeldM, Jaffe LS, Grant N, Gutierrez M, WaldmannTA and Wilson. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic largecell lymphoma. Blood 2004; 104: 3355 - 33576. Suzuki R, Kagami Y, Takeuchi K, Kami M, OkamotoM, Ichinohasama R, Mori N, Kojima M, YoshinoT, Yamabe H, Shiota M, Mori S, Ogura M, HamajimaN, Seto M, Suchi T, Morishima Y, Nakamura S. Prognosticsignificance of CD56 expression for ALK- positiveand ALK- negative anaplastic large – cell lymphomaof T/null cell phenotype. Blood;2000 96:2993-30007. Zhigui Ma, Cools J, Marynen P, Cui X, Siebert R,Gesk S, Schlegelberger B, Peeters B, Wolf-PeetersCD, Wlodarska I, and Morris SW Inv(2)(p23q35) inanaplastic large-cell lymphoma induces constitutiveanaplastic lymphoma kinase (ALK) tyrosine kinaseactivation by fusion to ATIC, an enzyme involvedin purine nucleotide biosynthesis Blood 2000; 95:2144 - 2149.8. Gascoyne BRD, Aoun P, Wu D, Chhanabhai M, SkinniderBF,Greiner TC, Morris SW, Connors JM, VoseJM, Viswanatha DS, Coldman, and WeisenburgerDD. Prognostic Significance of Anaplastic LymphomaKinase (ALK) Protein Expression in AdultsWith Anaplastic Large Cell Lymphoma Blood 1999;93: 3913 - 39219. Fanin R, Silvestri F, Geromin A, Cerno M, Infanti L,Zaja F, Barillari G, Savignano C, Rinaldi C, DamianiD, Buffoli A, Biffoni F, and Baccarani M. PrimarySystemic CD30 (Ki-1)- Positive Anaplastic LargeCell Lymphoma of the Adult: Sequential IntensiveTreatment with the F- MACHOP Regimen (+/-Radiotherapy)and Autologous Bone Marrow Transplantation.Blood1996:87:1243- 124810. Fanin R, Sperotto A, Silvestri F, Cerno M, GerominA, Stocchi R, Infanti L, Patriarca F, Zaja F, DamianiD, Baccarani M.. The therapy of primary adult systemicCD30-positive anaplastic large cell lymphoma:results of 40 cases treated in a single center. LeukLymphoma 1999; 35: 159-169.11. P Corradini, C Tarella, F Zallio, A Dodero, M Zanni,P Valagussa, AM Gianni, A Rambaldi, T Barbui, andS Cortelazzo. Long-term follow-up of patients withperipheral T-cell lymphomas treated up-front withhigh-dose chemotherapy followed by autologousstem cell transplantation. Leukemia 2006;20: 1533-153812. KW Zamkoff, MD Matulis, AC Metha, MW Beaty, REHutchison, and TC Gentile. High-dose therapy andautologous stem cell transplant does not result inlong-term disease-free survival in patients with recurrentchemotherapy-sensitive ALK-negative anaplasticlarge-cell lymphoma. Bone Marrow Transplantation2004;33: 635- 63813. E. Deconinck, T. Lamy, C. Foussard, F. Gaillard,V. Delwail, P. Colombat, P. Casassus, A. Lemevel,A. Brion1 and N. Milpied for the Groupe Ouest-estd’Etude des LeuceÂmies et Autres Maladies duSang (GOELAMS). Autologous stem cell transplantationfor anaplastic large-cell lymphomas: resultsof a prospective trial. British Journal of Haematology,2000;109, 736-74214. Willi Woessmann, Christina Peters, Meike Lenhard,Birgit Burkhardt, Karl–Walter Sykora, DagmarDilloo, Bernhard Kremens, Peter Lang, MonikaFührer, Thomas Kühne, Reza Parwaresch, WolframEbell and Alfred Reiter. Allogeneic haematopoieticstem cell transplantation in relapsed or refractoryanaplastic large cell lymphoma of children and adolescents-a Berlin- Frankfurt- Münster group report.British Journal of Haematology 2006;133: 176-182.Bibliografía LGI1. Lister, TA. The management of follicular lymphoma.Ann Oncol 1991; 2 :1312. Longo, D. What’s the deal with follicular lymphomas?J Clin Oncol 1993; 11:2023. Cogliatti, SB, Schmid, U, Schumacher, U, et al. PrimaryB-cell gastric lymphoma: A clinicopathologicalstudy of 145 patients. Gastroenterology 1991;101:1159.4. Harris, NL, Jaffe, ES, Stein, H, et al. A revised European-Americanclassification of lymphoid neoplasms:A proposal from the International LymphomaStudy Group. Blood 1994; 84:1361- 1392.5. Harris, NL, Jaffe, ES, Diebold, J, et al. World HealthOrganization classification of neoplastic diseasesof the hematopoietic and lymphoid tissues: Reportof the Clinical Advisory Committee meeting-AirlieHouse, Virginia, 1997. J Clin Oncol 1999; 17:3835.6. Carbone, PP, Kaplan, HS, Musshoff, K, et al. Reportof the committee on Hodgkin’s disease staging procedures.Cancer Res 1971; 31:1860.7. Musshoff, K. [Clinical staging classification of non-Hodgkin’s lymphomas (author’s transl)]. Strahlentherapie1977; 153:218.8. Radaszkiewicz, T, Dragosics, B, Bauer, P. Gastrointestinalmalignant lymphomas of mucosa-associatedlymphoid tissue: Factors relevant to prognosis.Gastroenterology 1992; 102:1628.9. Zucca, E, Bertoni, F, Roggero, E, et al. Molecularanalysis of the progression from Helicobacter pylori-associatedchronic gastritis to mucosa-associatedlymphoid-tissue lymphoma of the stomach. NEngl J Med 1998; 338:804.10. Wotherspoon, AC, Doglioni, C, Diss, TC, et al. Regressionof primary low-grade B-cell gastric lymphomaof mucosa-associated lymphoid tissue typeafter eradication of Helicobacter pylori. Lancet1993; 342:575.11. Roggero, E, Zucca, E, Pinotti, G, et al. Eradicationof Helicobacter pylori infection in primary low-gradegastric lymphoma of mucosa-associated lymphoidtissue. Ann Intern Med 1995; 122:767.12. Bayerdorffer, E, Neubauer, A, Rudolph, B, et al. Regressionof primary gastric lymphoma of mucosaassociatedlymphoid tissue type after cure of Helicobacterpylori infection. MALT Lymphoma StudyGroup. Lancet 1995; 345:1591.13. Steinbach, G, Ford, R, Glober, G, et al. Antibiotictreatment of gastric lymphoma of mucosa-associatedlymphoid tissue. Ann Intern Med 1999; 131:88.14. Chen, LT, Lin, JT, Tai, JJ, et al. Long-term results ofanti-Helicobacter pylori therapy in early-stage gastrichigh-grade transformed MALT lymphoma. J NatlCancer Inst 2005; 97:1345.15. Bertoni, F, Conconi, A, Capella, C, et al. Molecularfollow-up in gastric mucosa-associated lymphoidtissue lymphomas: early analysis of the LY03 cooperativetrial. Blood 2002; 99:2541-254416. Wundisch, T, Thiede, C, Morgner, A, et al. Long-® Cátedra de Hematología. Abril 2008. Montevideo, Uruguay59
Page 1 and 2:
Pautas de Diagnóstico y Tratamient
Page 3 and 4:
Consenso Nacional de Linfoma no Hod
Page 5 and 6:
Consenso Nacional de Linfoma no Hod
Page 7 and 8: Consenso Nacional de Linfoma no Hod
Page 57: Consenso Nacional de Linfoma no Hod
show all

Linfoma No Hodgkin

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?